Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

 
• By Alaric DeArment

The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.

Amgen presented data at WCLC for its bispecific antibody, tarlatamab, in small-cell lung cancer • Source: Shutterstock

More from Anticancer

More from Therapy Areas